Trial reportAnaesthesiology intensive therapy2024
Optimal dose of mivacurium for laser-assisted laryngeal microsurgery: a pharmacokinetic study using closed-loop target-controlled infusion.
Trial report in Anaesthesiology intensive therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mivacurium Infusion ED50/ED95 for Maintaining Motor Evoked Potentials During Adolescent Scoliosis Surgery Under TIVA: A Modified Dixon Up-and-Down Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMivacurium is a short-acting, non-depolarising neuromuscular blocking agent that provides adequate vocal cord myorelaxation during transoral laser microsurgery. This study aimed to determine the optimal dose of mivacurium by comparing the infusion rate delivered via a closed-loop target-controlled infusion system.
methodsA prospective, randomized clinical trial was conducted on 60 patients undergoing laser-assisted laryngeal microsurgery for vocal cord tumours. All patients received an induction mivacurium dose of 0.2 mg kg -1 and were randomized to 3 groups, namely C1, C2 and C3, each receiving infusion rates of 6 μg kg -1 min -1 , 7 μg kg -1 min -1 , 8 μg kg -1 min -1 , respectively. Neuromuscular monitoring and pharmacodynamic para-meters of mivacurium were recorded.
resultsNo cases of airway spasms, blood pressure or heart rate fluctuations were observed. Three patients had skin redness at the injection site. The onset time, no- response time, and recovery index (RI) of mivacurium did not differ significantly among the groups. However, additional mivacurium doses were needed for 15 patients in C1, 10 patients in C2, and 3 patients in C3 ( P 5.68 min was correlated with reduced mivacurium supplementation, and it was associated with no-response time and total mivacurium dose. The recovery index of all patients was also positively correlated with total mivacurium dosage ( p < 0.0001, r = 0.7838).
conclusionsA mivacurium infusion rate of 8 μg kg -1 min -1 offered the most favourable surgical field condition with no involuntary vocal cord movements, less need for supplementary doses, and fewer adverse reactions in laser-assisted laryngeal microsurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.